Literature DB >> 22218718

[Diabetes Care Austria 2009: registry for type 2 diabetic patients in general practitioners' ordinations in Austria].

Bernhard Ludvik1, Guntram Schernthaner.   

Abstract

Diabetes Care Austria was a nationwide data acquisition of type 2 diabetes treatment at Austrian general practitioners. A total of 5,385 general practitioners were contacted in the end of 2009; finally, 101 agreed to participate in the data collection. Out of all 9 Austrian provinces, a cross-sectional sample of 1.513 type 2 diabetic patients was investigated. Demographic data, diabetes treatment, quality of diabetes control as well as micro- and macrovascular complications were analysed with respect to diabetes duration, categorised into 6 classes. A total of 1.513 type 2 diabetic patients with a mean age of 65.4 ± 10.7 years and a mean diabetes duration of 8.7 ± 7.3 years were analysed. Metformin was equally used in more than 50% of patients in all classes of diabetes duration. The use of sulfonylureas was significantly (p < 0.001) increased from 25% in patients with a diabetes duration of less than 3 years to more than 40% in subjects with a disease duration of longer than 15 years. The prescription of glitazones was significantly (p = 0.02) augmented with increasing diabetes duration. DPP-4 inhibitors were used in more than 5% of patients with a maximum of 13% in subjects with a diabetes duration of 4-9 years (p < 0.001). The mean HbA1c was below 7.5% in all classes and was significantly (p < 0.01) the lowest with 7.0 ± 1.2% in patients with the shortest diabetes duration when compared to all other categories. Diabetes Care Austria yielded representative data for diabetes therapy of type 2 diabetic patients treated by general practitioners. Diabetes treatment was successful, as proven by a mean HbA1c value of 7.2%. An insulin therapy was initialised late, but was nevertheless effective as shown by comparable HbA1c values in patients with a diabetes duration of 4 to more than 15 years.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22218718     DOI: 10.1007/s00508-011-0120-y

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  31 in total

1.  Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients.

Authors:  Keiko Arai; Kiyokazu Matoba; Koich Hirao; Ikuro Matsuba; Masahiko Takai; Hiroshi Takeda; Akira Kanamori; Mikio Yamauchi; Hisao Mori; Yasuo Terauchi
Journal:  Endocr J       Date:  2010-03-06       Impact factor: 2.349

2.  Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

Authors:  Philip Raskin; Elsie Allen; Priscilla Hollander; Andrew Lewin; Robert A Gabbay; Peter Hu; Bruce Bode; Alan Garber
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

3.  Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

Authors:  A J Garber; T G Duncan; A M Goodman; D J Mills; J L Rohlf
Journal:  Am J Med       Date:  1997-12       Impact factor: 4.965

4.  Glucose control and vascular complications in veterans with type 2 diabetes.

Authors:  William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal:  N Engl J Med       Date:  2008-12-17       Impact factor: 91.245

5.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Authors:  Matthew C Riddle; Julio Rosenstock; John Gerich
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

6.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

7.  Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004.

Authors:  Wolfgang Rathmann; Burkhard Haastert; Andrea Icks; Guido Giani
Journal:  Diabetes Care       Date:  2007-04       Impact factor: 19.112

8.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  The effectiveness of the Austrian disease management programme for type 2 diabetes: a cluster-randomised controlled trial.

Authors:  Andreas C Sönnichsen; Henrike Winkler; Maria Flamm; Sigrid Panisch; Peter Kowatsch; Gert Klima; Bernhard Fürthauer; Raimund Weitgasser
Journal:  BMC Fam Pract       Date:  2010-11-05       Impact factor: 2.497

View more
  1 in total

1.  Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study.

Authors:  Helmut Brath; Christoph Bialek; Ewald Gingl; Michael Resl; Rudolf Prager; Michaela Ratzinger
Journal:  Wien Klin Wochenschr       Date:  2015-01-10       Impact factor: 1.704

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.